Shanghai Labway Clinical Laboratory Co Ltd Net Asset Quality Index
Shanghai Labway Clinical Laboratory Co Ltd net asset quality index. Shanghai Labway Clinical Laboratory Co Ltd (301060) has a Net Asset Quality Index of 71.6% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.35 Billion minus total liabilities of CN¥666.33 Million yields net assets of CN¥1.68 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 301060 book value for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Shanghai Labway Clinical Laboratory Co Ltd (2013–2025)
Net asset quality index of Shanghai Labway Clinical Laboratory Co Ltd from 2013 to 2025. This chart shows how Shanghai Labway Clinical Laboratory Co Ltd's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 71.6%, representing net assets of CN¥1.68 Billion against total assets of CN¥2.35 Billion CNY. Check how strategically is Shanghai Labway Clinical Laboratory Co L's equity deployed to assess the company's strategic physical and investment asset allocation.
Shanghai Labway Clinical Laboratory Co Ltd Net Asset Quality Index by Year (2013–2025)
Shanghai Labway Clinical Laboratory Co Ltd net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Shanghai Labway Clinical Laboratory Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market cap of Shanghai Labway Clinical Laboratory Co L.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 71.8% | CN¥1.64 Billion | CN¥2.29 Billion | CN¥647.39 Million | ▲ +2.4 pp |
| 2024 | 69.4% | CN¥1.82 Billion | CN¥2.62 Billion | CN¥803.00 Million | ▲ +3.1 pp |
| 2023 | 66.3% | CN¥1.98 Billion | CN¥2.99 Billion | CN¥1.01 Billion | ▲ +5.6 pp |
| 2022 | 60.7% | CN¥2.27 Billion | CN¥3.75 Billion | CN¥1.47 Billion | ▼ -17.2 pp |
| 2021 | 77.9% | CN¥1.64 Billion | CN¥2.11 Billion | CN¥465.67 Million | ▼ -6.9 pp |
| 2020 | 84.8% | CN¥1.25 Billion | CN¥1.47 Billion | CN¥224.13 Million | ▼ -1.9 pp |
| 2019 | 86.7% | CN¥1.21 Billion | CN¥1.40 Billion | CN¥185.89 Million | ▲ +4.9 pp |
| 2018 | 81.8% | CN¥1.18 Billion | CN¥1.44 Billion | CN¥262.15 Million | ▼ -1.2 pp |
| 2017 | 83.0% | CN¥1.10 Billion | CN¥1.33 Billion | CN¥225.66 Million | ▲ +17.9 pp |
| 2016 | 65.1% | CN¥614.70 Million | CN¥943.94 Million | CN¥329.25 Million | ▲ +11.2 pp |
| 2015 | 54.0% | CN¥305.25 Million | CN¥565.75 Million | CN¥260.50 Million | ▲ +10.5 pp |
| 2014 | 43.4% | CN¥201.13 Million | CN¥463.27 Million | CN¥262.14 Million | ▲ +3.7 pp |
| 2013 | 39.7% | CN¥130.79 Million | CN¥329.33 Million | CN¥198.54 Million | — |